In the rapidly evolving landscape of human genetics, the bottleneck is no longer the ability to sequence the human genome, but rather the ability to interpret the functional consequences of the variants discovered. As clinical sequencing becomes a standard diagnostic tool, physicians are increasingly faced with a mounting backlog of "variants of uncertain significance" (VUS). A new study published in Human Genetics and Genomics Advances (HGGA) offers a compelling blueprint for clearing this backlog, demonstrating how Drosophila melanogaster—the common fruit fly—can serve as a robust, scalable, and precise platform for clinical validation.
Dr. Hyung-lok Chung, an Assistant Professor at the Houston Methodist Research Institute and Weill Cornell Medical College, leads this charge. His latest research, titled "Loss-of-Function Variants in MARK2 Cause Neurodevelopmental Disorder," provides a definitive functional classification of genetic variants, offering long-awaited answers to affected families and a methodological template for the broader genetics community.
The Challenge of Interpretation: The MARK2 Case
The MARK2 project emerged from a long-standing, productive collaboration between Dr. Chung’s laboratory and the team led by Dr. Wendy K. Chung, a pioneer in clinical genomics and patient ascertainment. The primary goal of the study was to confirm whether specific variants in the MARK2 gene, identified in patients with neurodevelopmental disorders (NDD), were indeed the underlying cause of their conditions.
The research journey was not without its hurdles. Midway through their investigation, a separate research group published a case series in the American Journal of Human Genetics (AJHG) identifying MARK2 as an NDD-associated gene. While such an overlap can be discouraging for researchers, Dr. Chung chose to view it as an opportunity for differentiation.
"I felt that good science doesn’t lose its value just because someone else is working in the same area," Dr. Chung noted in an interview with HGGA. "Our study was doing something different—systematic, in vivo functional classification of patient-derived variants—which the clinical report did not cover." By shifting focus toward a comprehensive functional profile rather than mere discovery, the team successfully elevated the scientific discourse surrounding MARK2.
Methodology: The Drosophila Advantage
The study relied on "humanized" fly models, where the biological function of MARK2 was scrutinized in a living, multicellular organism. The researchers tested eight distinct NDD-linked variants across a battery of tissue-specific assays.
A Multidimensional Assessment
The strength of the study lies in its granularity. Instead of a single binary result—pathogenic or benign—the team utilized a four-tiered approach to analyze the variants:
- Viability: Assessing if the organism survives with the variant.
- Lifespan: Measuring the long-term impact on the fly’s health.
- Protein Expression: Determining how the variant affects the stability and presence of the protein.
- Wing Patterning: Observing developmental morphological changes, a classic readout for genetic signaling pathways.
By integrating these metrics, Dr. Chung and his team could categorize the variants into distinct functional groups: truncating variants were classified as "loss-of-function," most missense variants were labeled "hypomorphic" (partially functional), and one specific variant was identified as "not pathogenic," behaving no differently than the wild-type. This level of resolution is transformative for clinical interpretation, providing a roadmap for physicians to counsel families with higher accuracy.
Implications for Clinical Practice and Genetics
The impact of this work extends far beyond a single gene. As sequencing technology accelerates, the gap between data generation and biological understanding widens. Dr. Chung’s work serves as a proof-of-concept for how model organisms can bridge this divide.
Providing Clarity for Families
For families navigating the "diagnostic odyssey" of a rare disease, a variant of uncertain significance is often a source of immense psychological burden. "A genetic diagnosis is the first step," explains Dr. Chung, "but understanding what a variant actually does to protein function and brain development is what helps clinicians counsel families and think about next steps." By clarifying the functional status of MARK2 variants, the study allows for more precise clinical prognoses and, potentially, more targeted therapeutic approaches in the future.
Establishing a New Standard
The MARK2 study provides a framework that could be integrated into the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) guidelines. By establishing a standard procedure for functional validation in Drosophila, the research team hopes to make the interpretation of future MARK2 cases faster and more reliable.
To further this mission, Dr. Chung has launched the Houston Methodist Drosophila Functional Genomics Core. This facility is designed to offer functional validation services directly to clinician-scientists and human geneticists, effectively creating a bridge between bedside diagnostics and laboratory research.
The Life of an Independent Investigator
While the MARK2 paper has been a success, Dr. Chung is candid about the challenges faced by young investigators in the modern academic climate. The transition from a successful postdoctoral fellow to an independent PI is fraught with systemic pressures.
The Funding and Administrative Struggle
"Securing grant funding as a new PI takes a lot of effort—writing proposals, going through study sections, dealing with rejections, all while trying to build a lab at the same time," says Dr. Chung. He emphasizes that the "hidden curriculum" of academia—budgets, compliance, reporting, and mentorship—often consumes the mental bandwidth required for deep scientific thought.
A particularly difficult challenge is the "paradox of choice." A lab with the expertise to study rare disease gene discovery, sphingolipid metabolism, and viral interactions faces the constant risk of fragmentation. Dr. Chung notes that saying "not yet" to a brilliant, peripheral idea is as vital to a lab’s success as saying "yes" to the primary objective. He attributes his ability to remain focused to the institutional support at the Houston Methodist Research Institute and the Department of Neurology, which provided the infrastructure necessary to get his laboratory operational.
Future Horizons: Connecting Rare and Common Disease
When asked about the most fascinating developments in the field, Dr. Chung points to the convergence of rare and common disease genetics. He highlights recent large-scale whole-genome sequencing studies that have begun to uncover rare coding variants linked to common, complex neurodegenerative diseases like Parkinson’s, Alzheimer’s, and multiple sclerosis.
For years, research into these conditions was hindered by a reliance on genome-wide association studies (GWAS) that mostly identified variants in non-coding regions, making it difficult to pinpoint specific gene mechanisms. The discovery of rare coding variants—which have a larger functional impact—is beginning to close the gap between Mendelian, rare-disease research and the study of complex common disorders.
"For me, this is interesting because it means the functional genomics approaches we use for rare Mendelian disorders could also be applied to more common conditions," says Dr. Chung. "It is a good time to be in this field—the tools and data are finally catching up to the questions we have been asking for years."
Conclusion
The story of the MARK2 study is a microcosm of modern biological research. It highlights the tension between discovery and validation, the importance of interdisciplinary collaboration, and the critical need for scalable, functional models in the era of high-throughput sequencing. By transforming the Drosophila model into a high-precision diagnostic tool, Dr. Hyung-lok Chung is not only shedding light on the molecular underpinnings of neurodevelopmental disorders but is also helping to pave the way for a more personalized, functional approach to human genetics.
As the field continues to mature, the work of laboratories like Dr. Chung’s will be instrumental in ensuring that the data harvested from the human genome is transformed into meaningful, actionable insights for patient care. The future of genetics, it seems, lies not just in reading the code, but in understanding exactly how that code translates into the complex biological reality of life.
About the Author
